253 related articles for article (PubMed ID: 18544003)
1. Variability in the diagnosis and management of patients with Alzheimer's disease and cerebrovascular disease: results from the GALATEA multicentre, observational study.
Gil P; Ayuso JL; Marey JM; Antón M; Quilo CG
Clin Drug Investig; 2008; 28(7):429-37. PubMed ID: 18544003
[TBL] [Abstract][Full Text] [Related]
2. Understanding the role of psychiatrists in the diagnosis and management of mild cognitive impairment and mild Alzheimer's disease dementia: a cross-sectional survey.
Gopalakrishna G; Brunton S; Pruzin J; Alford S; Hamersky C; Sabharwal A
BMC Psychiatry; 2023 Oct; 23(1):716. PubMed ID: 37794326
[TBL] [Abstract][Full Text] [Related]
3. Clinical practice patterns of generalists and specialists in Alzheimer's disease: what are the differences, and what difference do they make?
Robinson L; Vellas B; Knox S; Lins K
J Nutr Health Aging; 2010 Aug; 14(7):545-52. PubMed ID: 20818469
[TBL] [Abstract][Full Text] [Related]
4. Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease.
Small G; Erkinjuntti T; Kurz A; Lilienfeld S
CNS Drugs; 2003; 17(12):905-14. PubMed ID: 12962529
[TBL] [Abstract][Full Text] [Related]
5. Management of suspected Alzheimer's disease patients by specialist physicians at the first visit in Spain: First Consultation Study.
Martínez Lozano MD; Guzmán Quilo C;
Expert Rev Neurother; 2011 May; 11(5):657-63. PubMed ID: 21539486
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease diagnosis disclosure in Brazil: a survey of specialized physicians' current practice and attitudes.
Raicher I; Shimizu MM; Takahashi DY; Nitrini R; Caramelli P
Int Psychogeriatr; 2008 Jun; 20(3):471-81. PubMed ID: 17822571
[TBL] [Abstract][Full Text] [Related]
7. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
[TBL] [Abstract][Full Text] [Related]
8. Prescribing patterns in dementia: a multicentre observational study in a German network of CAM physicians.
Jeschke E; Ostermann T; Vollmar HC; Tabali M; Schad F; Matthes H
BMC Neurol; 2011 Aug; 11():99. PubMed ID: 21824429
[TBL] [Abstract][Full Text] [Related]
9. [Treatment pattern of Alzheimer's disease with cholinesterase inhibitors (TRAIN study)].
Gil-Néciga E; Gobartt AL;
Rev Neurol; 2008 Apr 16-30; 46(8):461-4. PubMed ID: 18428102
[TBL] [Abstract][Full Text] [Related]
10. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's disease with cerebrovascular disease: current status in the Asia-Pacific region.
Chen C; Homma A; Mok VC; Krishnamoorthy E; Alladi S; Meguro K; Abe K; Dominguez J; Marasigan S; Kandiah N; Kim SY; Lee DY; De Silva HA; Yang YH; Pai MC; Senanarong V; Dash A
J Intern Med; 2016 Oct; 280(4):359-74. PubMed ID: 26992016
[TBL] [Abstract][Full Text] [Related]
12. Effect of galantamine on attention in patients with Alzheimer's disease combined with cerebrovascular disease.
Park JJ; Choi SH; Kim S; Lee AY; Moon SY; Lee JH; Kwon JC; Park KW; Ku BD; Han HJ; Kim EJ; Shim YS
Geriatr Gerontol Int; 2017 Oct; 17(10):1661-1666. PubMed ID: 27935239
[TBL] [Abstract][Full Text] [Related]
13. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
[TBL] [Abstract][Full Text] [Related]
14. Prescribing of drugs for Alzheimer's disease: a South African database analysis.
Truter I
Int Psychogeriatr; 2010 Mar; 22(2):264-9. PubMed ID: 20067653
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease.
Kurz AF; Erkinjuntti T; Small GW; Lilienfeld S; Damaraju CR
Eur J Neurol; 2003 Nov; 10(6):633-40. PubMed ID: 14641507
[TBL] [Abstract][Full Text] [Related]
16. Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease.
Reed BR; Mungas DM; Kramer JH; Ellis W; Vinters HV; Zarow C; Jagust WJ; Chui HC
Brain; 2007 Mar; 130(Pt 3):731-9. PubMed ID: 17267522
[TBL] [Abstract][Full Text] [Related]
17. [Patients' characteristics and clinical management of atrial fibrillation in primary healthcare in Spain: FIATE Study].
Lobos-Bejarano JM; del Castillo-Rodríguez JC; Mena-González A; Alemán-Sánchez JJ; Cabrera de León A; Barón-Esquivias G; Pastor-Fuentes A;
Med Clin (Barc); 2013 Oct; 141(7):279-86. PubMed ID: 23683967
[TBL] [Abstract][Full Text] [Related]
18. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
